Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis KEY MARKET PLAYERS Novo Nordisk A/S (Denmark) Eli Lilly and Company (US) Sanofi (France) Hansoh Pharmaceutical Group Co., Ltd
That follow-up trial, involving 536 obese adults over 24 weeks, failed to meet its primary efficacy endpoint, meaning the fat-loss effect seen at the smaller scale did not hold up in the pivotal study
it primarily reduces oxidative stress and brightens skin dullness
Key Benefits: Promotes melanin production for skin pigmentation and UV protection
J Nutr 135 , 978982 (2006)
However, the power for CV death and HHF subgroups was limited (29.34% and 79.22%, respectively), suggesting smaller effect sizes may not have been detected
